San Diego – February 21, 2019 – Cooley advised the underwriters on Gossamer Bio’s $317.4 million initial public offering of 19,837,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Partners Charlie Kim, Sean Clayton, David Peinsipp and Kristin VanderPas led the Cooley team advising the underwriters.
Prior to the re-opening of the SEC, the launch was scheduled to be the first healthcare IPO to pursue the creative solution of going public using an automatically effective registration statement during the government shutdown. It was also one of the largest healthcare IPOs of the last 20 years.
Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.
Gossamer Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol “GOSS,” is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,000+ lawyers across 14 offices in the United States, China and Europe.